Medimetriks Pharmaceuticals, Inc.
363 Route 46 West
Fairfield
New Jersey
07004-2402
United States
Tel: 973-882-7512
Fax: 973-882-7502
Website: http://medimetriks.com/
Email: info@medimetriks.com
23 articles about Medimetriks Pharmaceuticals, Inc.
-
Medimetriks Announces that Otsuka has Submitted MM36 (difamilast) New Drug Application for Approval in Japan
9/29/2020
Medimetriks Pharmaceuticals, Inc. today announced that Otsuka Pharmaceuticals Co. Ltd., submitted an application for approval of MM36 (difamilast) to the Japanese regulatory authorities. Positive MM36 results in two Phase 3 Japanese clinical trials in adult and pediatric patients with mild to moderate atopic dermatitis (AD) we
-
Medimetriks' MM36 (difamilast) Atopic Dermatitis Development Program Streamlined Following FDA Meeting
9/18/2020
Medimetriks Pharmaceuticals, Inc. today announced that the Company received a Type C Meeting Written Response from the U.S. Food and Drug Administration (FDA) regarding MM36 (difamilast) for the topical treatment of mild to moderate atopic dermatitis (AD).
-
Clinical Catch-Up: March 23-27
3/30/2020
Although some clinical trials are being slowed or halted, others are reporting out data. Here’s a look. -
Difamilast is a novel atopic dermatitis compound discovered by Otsuka.
-
Medimetriks Announces that Otsuka Achieved Positive Top-Line Phase 3 Results for MM36 (difamilast) in Japanese Adult and Pediatric Atopic Dermatitis Patients
3/26/2020
Medimetriks Pharmaceuticals, Inc. today announced that its partner, Otsuka Pharmaceuticals Co. Ltd., achieved positive results in two Phase 3 Japanese clinical trials in adult and pediatric patients for MM36 (difamilast), a novel topical, non-steroidal phosphodiesterase IV (PDE4) inhibitor for the treatment of mild to moderate atop
-
Medimetriks Pharmaceuticals Focuses on Advancing MM36 (difamilast) Through Phase 3 Trials; Extinguishes Debt Owed to Knight Therapeutics
6/18/2019
Medimetriks Pharmaceuticals, Inc. announced that the Company is in discussions for various financing options to advance MM36 (difamilast) through phase 3 pivotal trials and potential FDA approval.
-
Retrophin Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
7/30/2018
Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Noah L. Rosenberg, M.D., as chief medical officer, where he will oversee the clinical development of Retrophin’s product pipeline.
-
Medimetriks Pharma Receives FDA Approval for Xepi (ozenoxacin) Cream, 1%, a Novel Topical Antibiotic for Impetigo
12/14/2017
The approval of Xepi is based on a clinical development program that includes the results of two phase 3 trials.
-
Medimetriks Pharmaceuticals, Inc. Announces Phase II Study Results Demonstrating Early Itch Relief For Topical PDE4 Inhibitor MM36 In Patients With Atopic Dermatitis
9/6/2017
-
Medimetriks Pharmaceuticals, Inc.' New Drug Application For Ozenoxacin Cream, 1% Accepted For Review By FDA
8/31/2016
-
Medimetriks Pharmaceuticals, Inc. Submits A New Drug Application To FDA For Ozenoxacin Cream, 1%, A Novel Impetigo Treatment
6/27/2016
-
Medimetriks Pharmaceuticals, Inc. Announces The Results Of A Successful Phase 2 Trial Of MM36 In Atopic Dermatitis; Study Results And Design Published In The Journal Of The American Academy Of Dermatology (JAAD)
5/23/2016
-
Otsuka Pharma Licenses Pre-Phase 3 Topical Atopic Dermatitis Treatment To Medimetriks Pharmaceuticals, Inc.
2/9/2016
-
Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary And William Resnick To Its Board Of Directors
9/23/2014
-
Medimetriks Pharmaceuticals, Inc. Announces That The Second Phase 3 Study For Ozenoxacin Has Been Initiated By Ferrer
6/12/2014
-
Ferrer Internacional Licenses Commercialisation Rights For Ozenoxacin In The United States To Medimetriks Pharmaceuticals, Inc.
3/24/2014
-
IGI Laboratories, Inc. and Medimetriks Pharmaceuticals, Inc. Enter Long Term Strategic Partnership
12/8/2011
-
Zeltia Group's PharmaMar S.A. in Deal With US Medimetriks Pharmaceuticals, Inc.
6/10/2009
-
Medimetriks Pharmaceuticals, Inc. Launches Two New Prescription Brands
4/27/2009
-
Perrigo Company Appointed Generic Distributor by Medimetriks Pharmaceuticals, Inc.
1/26/2009